Y-39983

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H16N4O.ClH
Molecular Weight	316.785
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C[C@@H](N)C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2

InChI

InChIKey=IILQESWQPZIAGP-HNCPQSOCSA-N

InChI=1S/C16H16N4O.ClH/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15;/h2-10H,17H2,1H3,(H2,18,19,20,21);1H/t10-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H16N4O
Molecular Weight	280.3244
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800023536https://www.ncbi.nlm.nih.gov/pubmed/23258382
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20434334 | https://www.ncbi.nlm.nih.gov/pubmed/24684843 | https://www.ncbi.nlm.nih.gov/pubmed/24008512 | https://www.ncbi.nlm.nih.gov/pubmed/21667088

Y-33075 is potent and selective ROCK (Rho-associated coiled-coil-forming protein kinase) inhibitor, developed by Yoshitomi Pharmaceutical Industries for encephalomyelitis treatment. In rabbits and in monkeys, Y-33075 lowers IOP in a dose-dependent fashion. An increase in regenerating axons of RGCs in 100 mM Y-33075-treated eyes is observed compared with saline-treated eyes. Y-33075 dose-dependently increases the number of RGCs with regenerating axons. Both Y-33075 induces a concentration-dependent relaxation in rabbit ciliary arteries precontracted with a high-potassium (high-K) solution. The amplitude of relaxation induced by Y-33075 is not affected by either 100 μM N (G)-nitro-L: -arginine methyl ester (L: -NAME) or 10 μM indomethacin. In Ca2 -free solution, Y-27632 and Y-39983 significantly inhibit the transient contraction of ciliary arteries induced by 10 μM histamine. However, neither Y-27632 nor Y-39983 affects the elevation of [Ca2 ](i) induced by high-K solution and histamine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Rho-associated protein kinase 1 20 Target ID: CHEMBL3231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434334	Inhibitor 8504	30.0 nM [IC50]
Rho-associated protein kinase 2 25 Target ID: CHEMBL2973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24684843	Inhibitor 8504	58.0 nM [IC50]
Rho-associated protein kinase 7 Target ID: CHEMBL2111459 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17591891	Inhibitor 8504	3.6 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Encephalomyelitis 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24008512	Primary	Basic research	Unknown Approved Use Unknown
Ocular hypertension 52 Sources: http://adisinsight.springer.com/drugs/800023536	Primary	Phase II 1147	Unknown Approved Use Unknown
Open-angle glaucoma 53 Sources: http://adisinsight.springer.com/drugs/800023536	Primary	Phase II 1147	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P001ZQJ	https://www.1pchem.com/search?query=1P001ZQJ
1PlusChem LLC	1P002CKV	https://www.1pchem.com/search?query=1P002CKV
AK Scientific	4163AH	https://aksci.com/item_detail.php?cat=4163AH
AK Scientific	8982AA	https://aksci.com/item_detail.php?cat=8982AA
Angene	AGN-PC-0QAFEI	http://www.angenechemical.com/productshow/AGN-PC-0QAFEI.html
Angene	AGN-PC-0RUZDD	http://www.angenechemical.com/productshow/AGN-PC-0RUZDD.html
AstaTech	C15092	http://astatechinc.com/CPSResult.php?CRNO=C15092
BLD Pharm	BD237580	http://www.bldpharm.com/search/Search.html?keyword=BD237580
BLD Pharm	BD630514	http://www.bldpharm.com/search/Search.html?keyword=BD630514
BOC Sciences	173897-44-4	http://www.bocsci.com/description.asp?cas=173897-44-4
Chem Scene	CS-0096	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0096
Chem Scene	CS-0097	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0097
eMolecules	295311068	https://orderbb.emolecules.com/search/#?query=295311068
eMolecules	295311070	https://orderbb.emolecules.com/search/#?query=295311070
eMolecules	300722846	https://orderbb.emolecules.com/search/#?query=300722846
eMolecules	44469308	https://orderbb.emolecules.com/search/#?query=44469308
eMolecules	44811826	https://orderbb.emolecules.com/search/#?query=44811826
Lab Network	LN01343361	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343361
Lab Network	LN01343362	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343362
mcule	MCULE-8567762364	https://mcule.com/MCULE-8567762364/
MedChem Express	HY-10067	https://www.medchemexpress.com/search.html?q=HY-10067&ft=&fa=&fp=
MedChem Express	HY-10069	https://www.medchemexpress.com/search.html?q=HY-10069&ft=&fa=&fp=
MolPort	MolPort-023-333-598	https://www.molport.com/shop/molecule-link/MolPort-023-333-598
MolPort	MolPort-039-139-849	https://www.molport.com/shop/molecule-link/MolPort-039-139-849
MuseChem	I002265	https://www.musechem.com/product/I002265.html
MuseChem	I010115	https://www.musechem.com/product/I010115.html
Selleck Chemicals	S7935	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7935
Toronto Research Chemicals	A594890	https://www.trc-canada.com/product-detail/?CatNum=A594890
Toronto Research Chemicals	T704103	https://www.trc-canada.com/product-detail/?CatNum=T704103
Wonderchem	WD05E9A	http://www.wonder-chem.com/search.html?text=WD05E9A

PubMed

Title	Date	PubMed
Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension.	2015-08	25783615
In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.	2014-04-15	24684843
Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing.	2014-01-15	24106120
Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration.	2013-03	23258382
Y-39983, a selective Rho-kinase inhibitor, attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination.	2013	24008512
Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.	2011-10	21950703
Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.	2011-07	21667088
Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells.	2011	21850162
Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK.	2009-06	19456252
Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys.	2007-07	17591891
A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats.	2007-05	17359977
Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes.	2005-04	15682386

Patents

Sample Use Guides

In Vivo Use Guide

Senju Pharmaceuticals completed a phase II trial that evaluated the dose-response relationship of ocular hypotensive efficacy and safety of Y 39983 at concentrations ranging from 0.003%, 0.01%, 0.03% or Y 39983 vehicle control given twice a day for 4 weeks in patients with primary open angle glaucoma or ocular hypertension (UMIN000018866)

Route of Administration: Topical

In Vitro Use Guide

In medium containing 1 uM Y-39983, HUVECs exhibited contraction. The morphologic changes in HUVECs were reversible and had nearly recovered by 1 hour after removal of Y-39983

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:26:36 GMT 2025` Edited by `admin` on `Mon Mar 31 18:26:36 GMT 2025`
Record UNII	3304VH0J6B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Y-39983

Common Name

English

BENZAMIDE, 4-((1R)-1-AMINOETHYL)-N-1H-PYRROLO(2,3-B)PYRIDIN-4-YL-, HYDROCHLORIDE (1:1)

Preferred Name

English

Code System Code Type Description

ChEMBL

CHEMBL571948